3.0.0 543 2025-04-21T12:24:17Z 2025-04-21T12:24:17Z Senate S S 2023-02-28 118 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Referred To 2023-02-28T18:00:37Z 2023-02-28 sshr00 Health, Education, Labor, and Pensions Committee Senate Read twice and referred to the Committee on Health, Education, Labor, and Pensions. IntroReferral 2023-02-28 Introduced in Senate IntroReferral 10000 9 Library of Congress L000570 Sen. Lujan, Ben Ray [D-NM] Ben Lujan D NM R. N H001046 Sen. Heinrich, Martin [D-NM] Martin Heinrich D NM T. 2023-02-28 True Health Cardiovascular and respiratory health 2023-05-25T14:30:49Z Drug safety, medical device, and laboratory regulation 2023-05-25T14:30:49Z Drug therapy 2023-05-25T14:30:49Z Health care quality 2023-05-25T14:30:49Z Health facilities and institutions 2023-05-25T14:30:49Z Health information and medical records 2023-05-25T14:30:49Z Health promotion and preventive care 2023-05-25T14:30:49Z Medical research 2023-05-25T14:30:49Z Neurological disorders 2023-05-25T14:30:49Z Research administration and funding 2023-05-25T14:30:49Z Health 2023-03-21T23:30:55Z

00 2023-02-28 Introduced in Senate 2023-03-23T20:09:51Z <p><b>Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2023 or the CCM-CARE Act</b> <b>of 2023</b><br /><br />This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)<br /><br />The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.<br /><br />The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.<br /><br />The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways. </p>

Display Title 45 2024-07-24T15:23:36Z Short Title(s) as Introduced 101 2024-05-24T13:42:09Z Introduced in Senate IS Short Title(s) as Introduced 101 2024-05-24T13:42:09Z Introduced in Senate IS Official Title as Introduced 6 2023-03-14T06:30:45Z Introduced in Senate IS Introduced in Senate 2023-02-28T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-118s543is/xml/BILLS-118s543is.xml 2023-02-28 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.